Latest BioArctic News & Updates

See the latest news and media coverage for BioArctic. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioArctic

Research-oriented biopharma company for neurodegenerative diseases

bioarctic.com

Headquarters: Stockholm, Sweden
Founded year: 2003
Company type: Public company
Number of employees: 150–200
Industry: Pharmaceuticals

Last updated Today

Latest news about BioArctic

In short: BioArctic secured major R&D partnerships with Eli Lilly and Novartis while reporting record profits and expanded global use of Leqembi.

Company announcements

July 29 BioArctic

BioArctic reports Leqembi sales of 29.3 billion yen in Q2 2026

Royalties to BioArctic reached SEK 179 million, up 10% year-over-year. Excluding a stockpiling effect, growth was 43%.

July 13 BioArctic

BioArctic's partner Eisai receives FDA approval for Leqembi Iqlik

The once-weekly subcutaneous injection offers at-home dosing from initiation, with launch planned for late August 2026.

July 12 BioArctic

BioArctic presents new Leqembi SC autoinjector data at AAIC 2026

The subcutaneous formulation shows similar efficacy and safety to IV formulation in early Alzheimer's disease.

June 22 BioArctic

BioArctic and Lilly sign research and collaboration agreement

BioArctic receives USD 30 million upfront with up to USD 770 million in milestones for combining its BrainTransporter with a Lilly drug candidate.

Media coverage

July 29 Dagens industri

Bioarctic receives multi-million royalty after sales increase

The pharmaceutical company Bioarctic receives a sales-related royalty from its partner Eisai of 179 million kronor for the second quarter of 2026, which is...

July 20 Dagens PS

Alzheimer's shot approved in the USA – therefore Sweden says no

In the USA, new shots against Alzheimer's disease have been approved. But it seems that there will be nothing in the Nordic region. The US drug authority FDA has...

July 14 Dagens industri

The expert: Good news for Bioarctic

Bioarctic's Alzheimer treatment Leqembi can now be taken at home from the start. This could lead more patients to choose the treatment, and gives Bioarctic...

July 13 The Globe and Mail

Subcutaneous Leqembi Autoinjector Matches IV Exposure, Promises More Flexible Alzheimer’s Care

BioArctic’s partner Eisai reported at the Alzheimer’s Association International Conference that a once-weekly 500 mg subcutaneous Leqembi autoinjector achieved drug exposure bioequivalent to the ...

Never miss news about BioArctic

Track BioArctic and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioArctic competitors & trending companies

Browse news for competitors to BioArctic and other trending companies.